WO2000059942A3 - Human obesity protein binding protrein-2 homolog and uses thereof - Google Patents

Human obesity protein binding protrein-2 homolog and uses thereof Download PDF

Info

Publication number
WO2000059942A3
WO2000059942A3 PCT/US2000/006682 US0006682W WO0059942A3 WO 2000059942 A3 WO2000059942 A3 WO 2000059942A3 US 0006682 W US0006682 W US 0006682W WO 0059942 A3 WO0059942 A3 WO 0059942A3
Authority
WO
WIPO (PCT)
Prior art keywords
protrein
homolog
protein binding
bp2h
hob
Prior art date
Application number
PCT/US2000/006682
Other languages
French (fr)
Other versions
WO2000059942A2 (en
Inventor
Eric Wen Su
Jian-Jun Wei
Original Assignee
Lilly Co Eli
Eric Wen Su
Wei Jian Jun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Eric Wen Su, Wei Jian Jun filed Critical Lilly Co Eli
Priority to EP00917941A priority Critical patent/EP1169350A2/en
Priority to CA002365040A priority patent/CA2365040A1/en
Priority to JP2000609451A priority patent/JP2003500016A/en
Priority to AU38838/00A priority patent/AU3883800A/en
Publication of WO2000059942A2 publication Critical patent/WO2000059942A2/en
Publication of WO2000059942A3 publication Critical patent/WO2000059942A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention relates to at least one novel hOB-BP2h polypeptide, including isolated nucleic acids that encode at least one hOB-BP2h polypeptide, hOB-BP2h polypeptides, vectors, host cells, transgenics, chimerics, and methods of making and using thereof, as well as hOB-BP2h-specific antibodies and methods.
PCT/US2000/006682 1999-04-02 2000-03-22 Human obesity protein binding protrein-2 homolog and uses thereof WO2000059942A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00917941A EP1169350A2 (en) 1999-04-02 2000-03-22 Human obesity protein binding protein-2 homolog compositions and uses thereof
CA002365040A CA2365040A1 (en) 1999-04-02 2000-03-22 Hob-bp2h compositions, methods and uses thereof
JP2000609451A JP2003500016A (en) 1999-04-02 2000-03-22 hOB-BP2h compositions, methods and uses thereof
AU38838/00A AU3883800A (en) 1999-04-02 2000-03-22 Hob-bp2h compositions, methods and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12766799P 1999-04-02 1999-04-02
US60/127,667 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000059942A2 WO2000059942A2 (en) 2000-10-12
WO2000059942A3 true WO2000059942A3 (en) 2001-07-05

Family

ID=22431287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006682 WO2000059942A2 (en) 1999-04-02 2000-03-22 Human obesity protein binding protrein-2 homolog and uses thereof

Country Status (5)

Country Link
EP (1) EP1169350A2 (en)
JP (1) JP2003500016A (en)
AU (1) AU3883800A (en)
CA (1) CA2365040A1 (en)
WO (1) WO2000059942A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008257A2 (en) * 2000-07-21 2002-01-31 Bristol-Myers Squibb Company Siglec (sialic acid-binding ig-related lectin) polypeptides and uses thereof
WO2003083078A2 (en) 2002-03-28 2003-10-09 Bristol-Myers Squibb Company Novel human cell surface protein with immunoglobulin folds, bgs-19
ATE500842T1 (en) 2002-05-04 2011-03-15 Acorda Therapeutics Inc COMPOSITIONS AND METHODS FOR PROMOTING NEURONAL GROWTH
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
ES2887949T3 (en) * 2003-05-16 2021-12-29 Acorda Therapeutics Inc Proteoglycan-degrading mutants for CNS treatment
JP4926962B2 (en) 2004-05-18 2012-05-09 アコーダ セラピューティクス、インク． Purification method of chondroitinase and its stable preparation
AU2006294755B2 (en) 2005-09-26 2012-04-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
ZA200804162B (en) * 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
CA2666536C (en) 2006-10-10 2018-08-07 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH10286089A (en) * 1997-04-15 1998-10-27 Otsuka Pharmaceut Co Ltd Human gene
WO1998053840A1 (en) * 1997-05-27 1998-12-03 Smithkline Beecham Corporation SIALOADHESIN FAMILY 4 cDNA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH10286089A (en) * 1997-04-15 1998-10-27 Otsuka Pharmaceut Co Ltd Human gene
WO1998053840A1 (en) * 1997-05-27 1998-12-03 Smithkline Beecham Corporation SIALOADHESIN FAMILY 4 cDNA

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIRREN B. ET AL.: "Homo sapiens chromosome 15, clone RP11-300N24; Homo sapiens chromosome 15 clone RP11-300N24 map 15, LOW-PASS SEQUENCE SAMPLING", EMBL DATABASE ENTRY AC021676; ACCESSION NO. AC021676, 20 January 2000 (2000-01-20), XP002156745 *
CORNISH A L ET AL: "CHARACTERIZATION OF SIGLEC-5, A NOVEL GLYCOPROTEIN EXPRESSED ON MYELOID CELLS RELATED TO CD33", BLOOD, vol. 92, no. 6, 15 September 1998 (1998-09-15), pages 2123 - 2132, XP000913901, ISSN: 0006-4971 *
HILLIER L. ET AL.: "WashU-NCI human EST Project; ap33a07.x1 Schiller astrocytoma Homo sapiens cDNA clone IMAGE:1957140 3' similar to TR:O43700 O43700 CD33L2.; mRNA sequence", EMBL DATABASE ENTRY AI880327; ACCESSION NO. AI880327, 22 July 1999 (1999-07-22), XP002156744 *
LONNQVIST F. ET AL.: "Leptin and its potential role in human obesity", JOURNAL OF INTERNAL MEDICINE, vol. 245, no. 6, June 1999 (1999-06-01), pages 643 - 652, XP000925953 *
TAKEI Y ET AL: "MOLECULAR CLONING OF A NOVEL GENE SIMILAR TO MYELOID ANTIGEN CD33 AND ITS SPECIFIC EXPRESSION IN PLACENTA", CYTOGENETICS AND CELL GENETICS, vol. 78, 1997, pages 295 - 300, XP002066897, ISSN: 0301-0171 *

Also Published As

Publication number Publication date
JP2003500016A (en) 2003-01-07
WO2000059942A2 (en) 2000-10-12
CA2365040A1 (en) 2000-10-12
AU3883800A (en) 2000-10-23
EP1169350A2 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO1999055868A3 (en) Fizz proteins
WO2003016522A3 (en) Methods and compounds for the targeting of protein to exosomes
WO1999061469A3 (en) Prostate growth-associated membrane proteins
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO2003042362A3 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2003038041A3 (en) Il-4 mutein proteins, antibodies, compositions, methods and uses
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2002000718A3 (en) A human calcium channel protein and uses thereof
WO2000039297A3 (en) Il-1 related polypeptides
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2001083552A3 (en) Human sez6 nucleic acids and polypeptides
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2000037492A3 (en) Human hepatoma-derived growth factor homologous (huhdgfh) ____
WO2001066738A3 (en) Nucleic acids, encoding human crsp1 and uses thereof
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents
WO2003063767A3 (en) Rsv proteins, antibodies, compositions, methods and uses
WO2001042464A3 (en) Human preoptic regulatory factor-2 and uses thereof
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2365040

Country of ref document: CA

Ref country code: CA

Ref document number: 2365040

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609451

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000917941

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000917941

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09937636

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000917941

Country of ref document: EP